To include your compound in the COVID-19 Resource Center, submit it here.
Ligand began a Phase IIb/III trial to evaluate dinaciclib in patients with refractory CLL. The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury